Retrograde trafficking of VMAT2 and its role in protein stability in non-neuronal cells

Qiuzi Wu, Hongfei Xu, Wei Wang, Fei Chang, Yu Jiang, Yongjian Liu

PDF(312 KB)
PDF(312 KB)
Journal of Biomedical Research ›› 2016, Vol. 30 ›› Issue (6) : 502-509. DOI: 10.7555/JBR.30.20160061
Original Article

Retrograde trafficking of VMAT2 and its role in protein stability in non-neuronal cells

Author information +
History +

Abstract

Increasing evidence suggests that the impaired neuroprotection of vesicular monoamine transporter 2 (VMAT2) contributes to the pathogenesis of Parkinson's disease. That has been linked to aberrant subcellular retrograde trafficking as strongly indicated by recent genomic studies on familial Parkinson's diseases. However, whether VMAT2 function is regulated by retrograde trafficking is unknown. By using biochemistry and cell biology approaches, we have shown that VMAT2 was stringently localized to the trans-Golgi network and underwent retrograde trafficking in non-neuronal cells. The transporter also interacted with the key component of retromer, Vps35, biochemically and subcellularly. Using specific siRNA, we further showed that Vps35 depletion altered subcellular localization of VMAT2. Moreover, siRNA-mediated Vps35 knockdown also decreased the stability of VMAT2 as demonstrated by the reduced half-life. Thus, our work suggested that altered vesicular trafficking of VMAT2 may play a vital role in neuroprotection of the transporter as well as in the pathogenesis of Parkinson's disease.

Keywords

Parkinson's disease / VMAT2 / Vps35 / retrograde trafficking

Cite this article

Download citation ▾
Qiuzi Wu, Hongfei Xu, Wei Wang, Fei Chang, Yu Jiang, Yongjian Liu. Retrograde trafficking of VMAT2 and its role in protein stability in non-neuronal cells. Journal of Biomedical Research, 2016, 30(6): 502‒509 https://doi.org/10.7555/JBR.30.20160061

References

[1]
Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and patho genesis[J]. Annu Rev Pathol, 2011, 6: 193–222
Pubmed
[2]
Thomas, B. and M.F. Beal, Parkinson's disease[J]. Hum Mol Genet, 2007, R183–94.
[3]
Picconi B, Piccoli G, Calabresi P. Synaptic dysfunction in Parkinson's disease[J]. Adv Exp Med Biol, 2012, 970: 553–572
Pubmed
[4]
Kim-Han JS, Antenor-Dorsey JA, O'Malley KL. The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons[J]. J Neurosci, 2011, 31(19): 7212–7221
Pubmed
[5]
Liu Y, Peter D, Roghani A, A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter[J]. Cell, 1992, 70(4): 539–551
Pubmed
[6]
Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration[J]. Annu Rev Neurosci, 1997, 20: 125–156
Pubmed
[7]
Miller GW, Erickson JD, Perez JT, Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease[J]. Exp Neurol, 1999, 156(1): 138–148
Pubmed
[8]
Park JJ, Gondré-Lewis MC, Eiden LE, A distinct trans-Golgi network subcompartment for sorting of synaptic and granule proteins in neurons and neuroendocrine cells[J]. J Cell Sci, 2011, 124(Pt 5): 735–744
Pubmed
[9]
Liu Y, Edwards RH. Differential localization of vesicular acetylcholine and monoamine transporters in PC12 cells but not CHO cells[J]. J Cell Biol, 1997, 139(4): 907–916
Pubmed
[10]
Liu Y, Schweitzer ES, Nirenberg MJ, Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells[J]. J Cell Biol, 1994, 127(5): 1419–1433
Pubmed
[11]
Lohr KM, Miller GW. VMAT2 and Parkinson's disease: harnessing the dopamine vesicle[J]. Expert Rev Neurother, 2014, 14(10): 1115–1117
Pubmed
[12]
Onoa B, Li H, Gagnon-Bartsch JA, Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways[J]. J Neurosci, 2010, 30(23): 7917–7927
Pubmed
[13]
Nirenberg MJ, Liu Y, Peter D, The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei[J]. Proc Natl Acad Sci U S A, 1995, 92(19): 8773–8777
Pubmed
[14]
Waites CL, Mehta A, Tan PK, An acidic motif retains vesicular monoamine transporter 2 on large dense core vesicles[J]. J Cell Biol, 2001, 152(6): 1159–1168
Pubmed
[15]
Colgan L, Liu H, Huang SY, Dileucine motif is sufficient for internalization and synaptic vesicle targeting of vesicular acetylcholine transporter[J]. Traffic, 2007, 8(5): 512–522
Pubmed
[16]
Follett J, Norwood SJ, Hamilton NA, The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer[J]. Traffic, 2014, 15(2): 230–244
Pubmed
[17]
Zimprich A, Benet-Pagès A, Struhal W, A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease[J]. Am J Hum Genet, 2011, 89(1): 168–175
Pubmed
[18]
Vilariño-Güell C, Wider C, Ross OA, VPS35 mutations in Parkinson disease[J]. Am J Hum Genet, 2011, 89(1): 162–167
Pubmed
[19]
Rajendran L, Annaert W. Membrane trafficking pathways in Alzheimer's disease[J]. Traffic, 2012, 13(6): 759–770
Pubmed
[20]
Carlton J, Bujny M, Peter BJ, Sorting nexin-1 mediates tubular endosome-to-TGN transport through coincidence sensing of high- curvature membranes and 3-phosphoinositides[J]. Curr Biol, 2004, 14(20): 1791–1800
Pubmed
[21]
Wen L, Tang FL, Hong Y, VPS35 haploinsufficiency increases Alzheimer's disease neuropathology[J]. J Cell Biol, 2011, 195(5): 765–779
Pubmed
[22]
Follett J, Bugarcic A, Collins BM, Retromer's Role in Endosomal Trafficking and Impaired function in Neurodegenerative Diseases[J]. Curr Protein Pept Sci, 2016
Pubmed
[23]
Braschi E, Goyon V, Zunino R, Vps35 mediates vesicle transport between the mitochondria and peroxisomes[J]. Curr Biol, 2010, 20(14): 1310–1315
Pubmed
[24]
Nothwehr SF, Ha SA, Bruinsma P. Sorting of yeast membrane proteins into an endosome-to-Golgi pathway involves direct interaction of their cytosolic domains with Vps35p[J]. J Cell Biol, 2000, 151(2): 297–310
Pubmed
[25]
Liu Y, Krantz DE, Waites C, Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission[J]. Trends Cell Biol, 1999, 9(9): 356–363
Pubmed
[26]
Tan PK, Waites C, Liu Y, A leucine-based motif mediates the endocytosis of vesicular monoamine and acetylcholine transporters[J]. J Biol Chem, 1998, 273(28): 17351–17360
Pubmed
[27]
Chen CX, Huang SY, Zhang L, Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells[J]. Neurobiol Dis, 2005, 19(3): 419–426
Pubmed
[28]
Kim E, Lee Y, Lee HJ, Implication of mouse Vps26b-Vps29-Vps35 retromer complex in sortilin trafficking[J]. Biochem Biophys Res Commun, 2010, 403(2): 167–171
Pubmed
[29]
Seaman MN, Gautreau A, Billadeau DD. Retromer-mediated endosomal protein sorting: all WASHed up[J]! Trends Cell Biol, 2013, 23(11): 522–528
Pubmed
[30]
Temkin P, Lauffer B, Jäger S, SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signalling receptors[J]. Nat Cell Biol, 2011, 13(6): 715–721
Pubmed

Acknowledgments

This work was supported by the National Nature Science Foundation of China (Grant No.31371436 and No. 8157051134) and by the laboratory start-up grant from Nanjing Medical University to Y. Liu. We also thank Dr. Steven Cheng's lab for the assistance with confocal laser microscopy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

RIGHTS & PERMISSIONS

2016 2016 by the Journal of Biomedical Research. All rights reserved
PDF(312 KB)

Accesses

Citations

Detail

Sections
Recommended

/